Importantly, AR7, a specific activator of CMA, dramatically attenuates IMQ-induced psoriasiform lesions, resulting in a reduction of erythema, scaling, and skin thickening, as well as an increase in mouse weight. This evidence concerns the gene THRA and Erythema.